Clinical and Translational Oncology

, Volume 10, Issue 9, pp 587–590 | Cite as

Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab

  • Alicia Lázaro
  • Javier CassinelloEmail author
  • Almudena Amorós
  • Miriam Heredia
  • Ana López-Alfonso
Case Reports


A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.


Breast Cancer Chemotherapy Inflammatory Trastuzumab 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chang S, Parker SL, Pham T et al (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology and end results program of the National Cancer Institute, 1975–1992. Cancer 82:2366–2372PubMedCrossRefGoogle Scholar
  2. 2.
    Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis: inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429PubMedCrossRefGoogle Scholar
  3. 3.
    Palangie T, Mosseri V, Mihura J et al (1994) Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 7:921–927CrossRefGoogle Scholar
  4. 4.
    Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMedCrossRefGoogle Scholar
  5. 5.
    Carrick S, Ghersi D, Wilcken N et al (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database System Rev (2): CD003374Google Scholar
  6. 6.
    Konecny GE, Pegram MD (2004) Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park) 18[14 Suppl 12]: 32–36Google Scholar
  7. 7.
    Crown J, Pegram M (2003) Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79[Suppl 1]:S11–18PubMedCrossRefGoogle Scholar
  8. 8.
    Martin M (2001) Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2:190–208; discussion 209PubMedCrossRefGoogle Scholar
  9. 9.
    Vogel C, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single-agent in first line treatment of Her2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726PubMedCrossRefGoogle Scholar
  10. 10.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  11. 11.
    Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246–3250PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  • Alicia Lázaro
    • 1
  • Javier Cassinello
    • 2
    Email author
  • Almudena Amorós
    • 1
  • Miriam Heredia
    • 1
  • Ana López-Alfonso
    • 2
  1. 1.Servicio de Farmacia HospitalariaHospital Universitario de GuadalajaraGuadalajaraSpain
  2. 2.Sección de Oncología MédicaHospital Universitario de GuadalajaraGuadalajaraSpain

Personalised recommendations